Cambridge Trust Co. Purchases 467 Shares of Boston Scientific Co. (NYSE:BSX)

Cambridge Trust Co. raised its position in Boston Scientific Co. (NYSE:BSX) by 14.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,647 shares of the medical equipment provider’s stock after buying an additional 467 shares during the quarter. Cambridge Trust Co.’s holdings in Boston Scientific were worth $211,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in BSX. Bruce G. Allen Investments LLC bought a new position in Boston Scientific during the fourth quarter worth about $28,000. Sunbelt Securities Inc. purchased a new position in Boston Scientific in the 1st quarter valued at approximately $32,000. Motco raised its holdings in Boston Scientific by 136.3% during the 3rd quarter. Motco now owns 645 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 372 shares during the period. Venturi Wealth Management LLC lifted its position in shares of Boston Scientific by 58.0% during the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 215 shares in the last quarter. Finally, Coppell Advisory Solutions LLC purchased a new position in shares of Boston Scientific in the second quarter valued at $34,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

BSX stock opened at $67.33 on Friday. The stock has a market capitalization of $98.78 billion, a price-to-earnings ratio of 62.93, a PEG ratio of 2.38 and a beta of 0.78. The firm’s 50-day moving average price is $67.25 and its two-hundred day moving average price is $59.84. The company has a current ratio of 1.32, a quick ratio of 0.82 and a debt-to-equity ratio of 0.44. Boston Scientific Co. has a 12-month low of $48.35 and a 12-month high of $69.21.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of $0.51 by $0.04. Boston Scientific had a return on equity of 15.99% and a net margin of 11.19%. The business had revenue of $3.73 billion during the quarter, compared to analyst estimates of $3.59 billion. During the same quarter in the prior year, the company posted $0.45 EPS. As a group, equities analysts predict that Boston Scientific Co. will post 2.25 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. JPMorgan Chase & Co. raised their target price on Boston Scientific from $60.00 to $72.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Raymond James raised their price objective on shares of Boston Scientific from $67.00 to $73.00 and gave the company a “strong-buy” rating in a research report on Thursday, February 1st. StockNews.com lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 16th. Needham & Company LLC raised their price objective on shares of Boston Scientific from $60.00 to $71.00 and gave the company a “buy” rating in a research report on Thursday, February 1st. Finally, BTIG Research restated a “buy” rating and issued a $64.00 price objective on shares of Boston Scientific in a research report on Friday, December 29th. Two equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $68.50.

Insider Buying and Selling at Boston Scientific

In other news, CFO Daniel J. Brennan sold 13,662 shares of Boston Scientific stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total transaction of $899,779.32. Following the sale, the chief financial officer now owns 271,542 shares of the company’s stock, valued at approximately $17,883,756.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Boston Scientific news, CFO Daniel J. Brennan sold 13,662 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total value of $899,779.32. Following the completion of the sale, the chief financial officer now directly owns 271,542 shares in the company, valued at $17,883,756.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP John Bradley Sorenson sold 16,351 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $69.30, for a total value of $1,133,124.30. Following the transaction, the executive vice president now owns 50,638 shares in the company, valued at approximately $3,509,213.40. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,979 shares of company stock valued at $3,418,529. 0.50% of the stock is currently owned by company insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.